Jaguar Health Schedules Webcast on Crofelemer Trial Results

The latest update is out from Jaguar Animal Health ( (JAGX) ).

On April 28, 2025, Jaguar Health announced an investor webcast scheduled for April 30, 2025, to discuss preliminary results from a proof-of-concept trial of crofelemer for treating rare diseases like microvillus inclusion disease and short bowel syndrome with intestinal failure. The webcast will cover patient experiences, the drug’s impact on disease progression, and potential regulatory pathways, highlighting Jaguar’s commitment to addressing unmet clinical needs and its strategic positioning in the pharmaceutical industry.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Underperform.

Jaguar Animal Health’s overall stock score is low primarily due to substantial financial challenges, including high leverage and negative profitability. Technical analysis suggests bearish trends, and valuation metrics are unappealing. While recent earnings calls and corporate events provide some optimism with revenue growth and potential regulatory advancements, ongoing net losses and clinical trial challenges continue to weigh heavily on the stock’s potential.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. The company, through its family companies Napo Pharmaceuticals and Napo Therapeutics, focuses on human prescription pharmaceuticals for managing neglected gastrointestinal symptoms and expanding crofelemer access in Europe for orphan and/or rare diseases.

YTD Price Performance: -56.79%

Average Trading Volume: 87,476

Technical Sentiment Signal: Buy

Current Market Cap: $7.35M

See more insights into JAGX stock on TipRanks’ Stock Analysis page.